Audion Therapeutics is a clinical-stage company that specializes in developing innovative therapies to address Hearing Loss. Their primary focus is on regenerating cells and neuronal connections that are lost in patients with acquired Sensorineural Hearing Loss (SNHL), which is the most common form of Hearing Loss. The foundation of Audion's program is based on groundbreaking scientific discoveries from the Edge lab at Massachusetts Eye and Ear Infirmary (MEEI).

Through collaboration with MEEI and Eli Lilly, Audion has licensed and developed a range of technologies and small molecules that form their intellectual property and knowhow. Their lead product, AUD1001 (LY3056480), is a gamma secretase inhibitor. Initial clinical studies have demonstrated the safety and efficacy of this approach.

In fact, a phase I/IIa clinical study across three sites in Europe showed promising results, with significant improvements observed in hearing tests for multiple patients. With a dedicated management team and board of directors, Audion Therapeutics is committed to transforming the lives of individuals with Hearing Loss through cutting-edge therapies and advancements in the field